Abbott Laboratories vs. PTC Therapeutics, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | PTCT | |
|---|---|---|
| Market Cap | $192.51 billion | $5.98 billion |
| Revenue (TTM) | $46.59 billion | $1.01 billion |
| Net Income (TTM) | $5.42 billion | $-38,382,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | PTCT | |
|---|---|---|
| P/E Ratio | 36.00 | — |
| Price / Book | 3.72 | -36.19 |
| Price / Sales | 4.13 | 5.93 |
ABT and PTCT split the valuation factors evenly.
Profitability
| ABT | PTCT | |
|---|---|---|
| Net Margin | 11.65% | -3.80% |
| Return on Equity | 10.48% | 23.21% |
ABT and PTCT split the profitability factors evenly.
Dividend
| ABT | PTCT | |
|---|---|---|
| Dividend Yield | 2.27% | — |
| Payout Ratio | 81.55 | — |
ABT and PTCT split the dividend factors evenly.
Risk & Sentiment
| ABT | PTCT | |
|---|---|---|
| Short Interest | 0.57% | 7.88% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, PTCT overview, PTCT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.